MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
References
The Veterinary Record has published what the British Homeopathy Association is calling the first ever systematic review of randomised controlled trials (RCTs) in veterinary homeopathy.
The review was conducted by Dr Robert Mathie, research development adviser to the association, and Dr Jürgen Clausen from the Carstens Foundation, Germany.
They found 18 placebo-controlled RCTs of veterinary homeopathy, published in the peer-reviewed literature, that were eligible for detailed assessment. Of these, only two were judged to provide reliable evidence. The remainder were unclear or had a high risk of bias.
The two studies which were judged reliable were:
HEKTOEN, L., LARSEN, S., ØDEGAARD, S. A. & LOKEN, T. (2004) Comparison of homeopathy, placebo and antibiotic treatment of clinical mastitis in dairy cows - methodological issues and results from a randomized-clinical trial. Journal of Veterinary Medicine. A, Physiology, pathology, clinical medicine 51, 439-446. In this study, homeopathy was shown to be ineffective.
Dr Mathie said: "Up to now, debates about the efficacy or effectiveness of veterinary homeopathy have been polarised by the absence of any systematic review of the subject. Our work clarifies the nature of the current RCT evidence."
Mr Mark Elliott, immediate past president of the British Association of Homeopathic Veterinary Surgeons, said: "This important study affirms that reliable evidence does exist and that more research should be done, particularly in light of current concerns about antibiotic resistance in production animals."
It seems a remarkable admission, that the entire veterinary homeopathy edifice rests upon one study in piglets. However, if that study did prove the efficacy of homeopathy, it would of course be an order of magnitude more remarkable than today's admission.
So, no pressure then, Camerlink et al!
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
MSD Animal Health has launched Zuprevo Cattle, which contains a novel antibiotic molecule to help combat bovine respiratory disease (BRD).
Zuprevo Cattle contains the active ingredient tildipirosin (180mg/ml), a new 16-membered, tribasic macrolide unique to animal health. It is licensed for the treatment and prevention of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
According to MSD Animal Health livestock veterinary adviser Paul Williams MRCVS, the new product works extremely quickly in the animal, as well as offering the longest duration of activity in the lungs of all the macrolide antibiotics currently on the market. He says it is also extremely convenient to use: "Zuprevo is readily absorbed by the animal, reaching peak plasma concentrations within 23 minutes of injection. Zuprevo is readily distributed around the body and reaches lung concentration well above MIC90 for all of the three BRD target pathogens within four hours of administration. In addition, it maintains lung concentration above the MIC90 for up to 28 days, which will appeal to many practitioners."
Paul says that it is Zuprevo's 16-membered, tribasic macrolide structure that allows it to deliver these significant pharmacological benefits for the management of BRD in cattle: "Zuprevo works by diffusing into the bacterial cell where its binding action inhibits protein synthesis of the bacterial ribosome. Its unique 16-membered, tribasic structure enables enhanced penetration of the bacterial cell wall, as well as having the ability to bypass some potential bacterial resistance mechanisms."
Paul says Zuprevo also offers vets and their farmer clients important practical usage advantages: "Zuprevo is an easily syringeable solution for injection available in convenient 20ml, 50ml and 100ml vial sizes to suit different usage requirements. At a dose rate of 1ml/45kg, it offers the lowest macrolide dose volume per kg of bodyweight. At 47 days, Zuprevo also has the shortest macrolide meat withdrawal period."
Further information on this new macrolide antibiotic is available from the MSD Animal Health territory managers or by calling the company's Veterinary Services Group on 01908 685685.
Bayer Animal Health has launched Baytril® Max 100mg/ml Solution for Injection for Cattle and Pigs, which replaces the company's previously animal-specific Baytril Max products.
Bayer says the active ingredient, enrofloxacin, treats bacterial infection by inhibiting the action of bacterial DNA gyrase resulting in bacterial cell death.
In cattle, Baytril Max treats respiratory infections and mastitis caused by enrofloxacin-sensitive Histophilus somni, Mannheimia haemolytica, Pasteurella multocida and Mycoplasma spp., and enrofloxacin-sensitive E. coli respectively.
In pigs, Baytril Max targets bacterial bronchopneumonia caused by enrofloxacin-sensitive Actinobacillus pleuropneumoniae, Pasteurella multocida and complicated by Haemophilus parasuis as a secondary pathogen in pigs.
Bayer advises that vets treating cattle for respiratory infections should inject subcutaneously. Mastitis cases should be treated intravenously and pigs should be injected intramuscularly in the neck muscles, behind the ear.
The development of the Baytril Max product family provides vets with greater treatment flexibility from one solution.
For further information please visit www.noahcompendium.co.uk
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
The current strain of bluetongue emerged in the Netherlands in 2023 and spread rapidly, infecting over 5,000 livestock farms.
Infection of livestock with this serotype of the virus can result in severe clinical signs and high mortality rates1, significantly impacting animal health, and farming communities.
Bultavo 3 is an inactivated injectable vaccine indicated for the active immunisation against BTV-3.
Boehringer says that in sheep, Bultavo 3 has been shown to significantly reduce viraemia and prevent mortality and clinical signs associated with BTV-3 infection.
Onset of immunity occurs three weeks after administration of a single 1ml subcutaneous dose in sheep.
In cattle, two 1ml intramuscular doses are required, at a three-week interval.
Findlay MacBean, Head of Livestock, UK and Ireland at Boehringer Ingelheim, said: “It’s great news that we can support farmers and authorities in their fight against bluetongue with our new BTV-3 vaccine, Bultavo 3.
"As we have seen across Europe, and now in the UK, BTV can spread rapidly and causes considerable stress to farmers because of the significant financial impact on those affected.
The availability of Bultavo 3 means future BTV-3 outbreaks can be suppressed, helping farmers protect not only their herds, but also their livelihoods.” Oli Maxwell, BVSc BSc(Hons) MVM DipECBHM, RCVS Recognised Specialist in Cattle Health and Production and Clinical Director of Green Counties Vets said: “Farmers are justifiably concerned about BTV-3 and its incursion into the UK again this year.
"Reports from colleagues on the continent regarding the severity of clinical signs, especially in sheep are worrying.
"We have seen a huge increase in clients asking about the disease, progress on a vaccine and what this may mean for animal movements at a critical time of year.
"The availability of a safe and effective vaccine as a critical tool against a disease that we can’t reasonably prevent with biosecurity measures will be a welcome development for many.”
To manage supply and demand, use of the product will initially be subject to geographical restriction with vaccination permitted in high-risk English counties: Norfolk, Suffolk, Essex, Kent and East Sussex.
Reference:
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
The award, funded by the Economic and Social Research Council (ESRC) working in partnership with the Department of Health and the Arts and Humanities Research Council (AHRC), is part of the cross-council 'Tackling antimicrobial resistance: behaviour within and beyond the healthcare setting’ call, part of the antimicrobial resistance cross-council initiative supported by the seven research councils in partnership with other UK funders including the Medical Research Council (MRC).
The research team will be led by social scientists at the University of Exeter and includes two veterinary surgeons from the University of Bristol’s School of Veterinary Sciences, together with colleagues at the Innogen Institute of the University of Edinburgh, the British Veterinary Association and leading farm animal veterinary surgeons across the UK.
The researchers say that better, smarter, more rapid and more accessible diagnoses - driving shifts in behaviour associated with diagnostic decision making - represent a critical step to delivering more effective uses of antibiotics in animal health. But improvements in diagnostic development and their relationship to prescription and treatment requires social, governance and technical innovations.
Professor Henry Buller, project lead from the University of Exeter’s School of Geography, said: "This is an exciting opportunity to provide a current assessment of diagnostic and treatment decision practices in the livestock sectors of the UK. Novel and innovative diagnostic tools are currently in development, and our research will generate better understanding of their development as well as the marketing and regulation of these new technologies."
Dr Kristen Reyher, Senior Lecturer in Farm Animal Science, who is the lead on the project at the University of Bristol’s School of Veterinary Sciences, added: "Our research team – the AMR Force – has a track record of working closely with farmers, veterinarians, retailers and government bodies to encourage responsible use of antibiotics. We are excited to have this amazing opportunity to collaboratively generate, evaluate and analyse behaviours and strategies around animal disease diagnosis and to show how innovation in the development of diagnostic tools along with diagnostic regulation and governance can lead to more sensible use of antibiotics across farming systems.
"Working with our partners, we will identify pathways and possibilities for improved diagnostic practice and will trial new diagnostic tools on a series of farms. We are very excited to take our ideas beyond the UK as well, and will conduct pilot and capacity-building research in Tanzania and also partner with a project working in Bangladesh that is co-funded by ESRC and the Centre for Environment Fisheries and Aquaculture Science."
Professor Buller added: "Employment of new diagnostics doesn’t occur in a vacuum. Our team will evaluate the implications these innovations will have for the organisation, cost-effectiveness and efficiency of veterinary practice, as well as for veterinary training. We will identify the changes in behaviour, practice and knowledge necessary to accompany the more widespread adoption of practices that are deemed effective and will assess the regulatory and governance support necessary to encourage use of beneficial practices."
The interdisciplinary team will work alongside diagnostic tool developers and regulators, veterinary practices and professional bodies, farmers and treatment decision makers, veterinary laboratories, the food industry and government regulatory authorities to develop durable and innovative strategies for facilitating and advancing smarter approaches to the use of antibiotics in agriculture.
The work will cover the major livestock species, and will involve seeking opinions from veterinary surgeons across the country, through collaboration with the BVA.
David Barrett, Professor of Bovine Medicine, Production and Reproduction at the University of Bristol’s School of Veterinary Sciences, said: "This is a fantastic opportunity to assess the adaptability and responsiveness of the different animal production sectors - poultry, pigs and cattle - along with a variety of veterinary structures to the trialled innovations in diagnosis and diagnostics, and will determine the likely benefits of these innovations for prescription practice, for animal health and for sustainable livestock production."
Photo: University of Bristol
The British Veterinary Association has welcomed the tightening up of sales of veterinary medicines on the internet but has expressed disappointment that the advertising of antimicrobials to farmers will continue.
The Veterinary Medicines Directorate has today published its response to the public consultation on the Veterinary Medicines Regulations, which are updated every year.
The new Regulations, which come into force in April 2011, introduce new controls on internet pharmacies meaning that only approved websites will be legally allowed to dispense and supply veterinary medicines. The controls will come into force in April 2012 and the BVA supports the use of a logo on approved websites to help consumers buy medicines from reputable sources.
The BVA has previously expressed concern that pet owners could inadvertently buy counterfeit veterinary medicines online and urges veterinary clients to seek advice from their vet and only buy from UK-based companies.
Harvey Locke, President of the BVA, said: "Without proper regulation online pharmacies could be sourcing drugs from overseas and selling counterfeit medicines that look genuine to unsuspecting pet owners. These medicines are placebos at best and dangerous at worst.
"We therefore welcome the VMD's decision to clampdown on irresponsible online retailers and provide a clear logo for approved websites that will give pet owners confidence.
"We have also asked the VMD to put a stop to the increasing problem of prescription fraud and we hope the tighter regulation announced today will be a step towards achieving that aim.
"However, we would urge all pet owners to continue talking to their vet about sourcing medicines from the internet to make sure the right drugs are bought and administered correctly."
In light of increasing concerns about the growth of antimicrobial resistance the VMD's consultation canvassed views on restricting the advertising of antimicrobials to farmers. The BVA says it supported a ban on advertising as a sensible approach to the responsible use of antimicrobials, and is disappointed that the VMD has decided not to go ahead with it. Mr Locke said: "New antimicrobials are heavily advertised by pharmaceutical companies to vets and farmers so it is vital that the message of responsible use is not lost.
"Antimicrobial resistance is a serious issue for both animal and human health and we are disappointed that the VMD is not restricting the advertising of these products to farmers. The pharmaceutical companies must now undertake to advertise responsibly.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets and farmers should work together to ensure antimicrobials are used prudently and responsibly."
Eurovet Animal Health has launched Marbiflox 10%, a new marbofloxacin preparation for the treatment of respiratory infections in cattle and pigs.
Eurovet says the product can be used flexibly to provide a single dose treatment, with a concentration-dependent effect and a relatively short withdrawal period. Marbiflox can be administered intravenously, subcutaneously or intramuscularly in cattle or intramuscularly in pigs.
The main indications, with reference to good prescribing practice, are for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni and acute forms of mastitis induced by marbofloxacin-sensitive Escherichia coli strains, during lactation. In pigs the main indication is in the treatment of MMA (metritis mastitis agalactia syndrome).
Further information about Marbiflox and the complete Eurovet range of products is available from Eurovet Animal Health. www.eurovet-ah.co.uk/.
The Royal Veterinary College has launched an appeal to the veterinary profession to raise a target of £10,000 to enable VetAid Kenya to help during what has become the worst drought in living memory in the Horn of Africa.
According to the RVC, the drought has already forced over one million cattle and small stock south into the Tana Delta district of Kenya in search of grazing. Crowded together, these weakened animals are at major risk of infectious and parasitic disease. In some cases 80-90% mortality can be expected in herds or flocks. Without veterinary intervention, breeding livestock for communities in the Horn of Africa drought area will be devastated.
Government veterinary services are stretched and they are assisted in a coordinated response involving Vétérinaires Sans Frontières (Belgium, Switzerland and Germany) and VetAid Kenya which has staff in the field protecting herds. The programme has been partly funded by the Food and Agriculture Organisation (FAO), but with funds running low this vital activity is at risk just as it is most needed. VetAid Kenya is now the only veterinary agency working in the area, implementing an emergency vaccination programme to protect the breeding stock.
Gabriel Turasha, Director of VetAid Kenya said: "We only have one team working in Tana River and desperately need funds to send out three more teams as soon as possible. £10,000 would cover the cost of three teams, transport and vaccinations to treat 20,000 animals per week. This will make a real difference as we are providing the only veterinary support in this vast area.
"Our vaccination teams are ready to go out into the field at a few days notice. We just need to mobilize them. This is where the UK veterinary profession can help - every pound donated will make a huge difference!"
RVC Principal Professor Stuart Reid said: "Veterinary services are seriously stretched in Kenya and the only organisations with the flexibility, initiative and expertise to respond this to emergency are the veterinary NGOs such as VetAid Kenya and its Vétérinaires Sans Frontières partners.
"FAO has limited budget to spend on disaster response and RVC has a longstanding relationship with VetAid Kenya and with the region in general. As a College, we strongly feel that we should do all we can to support pastoral farmers in the region, and mounting this appeal is one way in which we can respond to the ongoing disaster and support our veterinary colleagues in East Africa."
The RVC and all other agencies involved in this appeal are contributing their services pro-bono so that all funds raised will go to the programme to help the people and animals struggling with the drought.
To donate, visit: www.rvc.ac.uk/vetaidkenya
Current estimates suggest that around 95,000 calves, 30 million chicks and 3,000 Billy kids are affected per year.
The new position calls for solutions based on the overarching principle that quality of life should take precedence over lifespan, with the longer-term aim to move away from the production of unwanted animals all together. In the meantime, the position calls for further research into solutions to reduce numbers of additional male offspring and for humane methods of killing surplus animals on-farm.
The dairy and egg industries have been advised to adopt a ‘3Rs’ (reduce, replace, refine) approach to the rearing and slaughter of animals which are surplus to the requirements of the specific industries. Reduction recommendations include selecting for sex (a technology used quite frequently within the dairy farming community) and increasing the length of time that an animal can produce milk through selective breeding.
In the absence of these options, the position recommends raising male offspring for meat, with the caveat that calves and billy goat kids should be raised within UK high welfare schemes only.
In the absence of any reduce or replacement options, veterinary experts advise that killing should be undertaken in the most humane way and that all the animal’s welfare needs must be addressed prior to slaughter.
In line with BVA’s sustainable animal agriculture position, this policy recommends that when animals are killed, every effort should be made to make sure that the carcass is used. For example, the carcasses of male chicks killed by controlled atmospheric stunning can be used in animal feed, such as for reptiles and birds of prey.
BVA Junior Vice President, James Russell (pictured right) said: "Unwanted male production animals in the dairy and meat industries are an ethical challenge on a number of levels. Firstly, for the producer who may have animals with little or no commercial value. Secondly, for the consumer who may find the notion of these unused animals a difficulty. Our new joint position is based around the principle of ‘a life worth living’ and looks at ways that the veterinary profession can work with the farming community to reduce the numbers of animals that this affects and ensure that high welfare is always front and centre.
"If slaughter of affected animals is undertaken humanely, it is not a welfare harm per se, but greater measures should be taken to make sure that these decisions are made with minimal carcass wastage and an eye to the economic, emotional and environmental impact at a farm level.
"With greater public understanding of ethical and animal welfare issues faced by the industry, the promotion of farm assurance schemes and further research into alternative breeding options such as selective sex technology, we hope to reduce these numbers and improve the welfare of the animals involved."
BCVA President, Professor David Barrett said: "The number of unwanted male dairy calves has fallen substantially in recent years, due in part to more efficient milk production meaning we now need fewer dairy cows to produce the same volume of milk, as well as the use of breeding technologies that mean we can select for female calves. Nevertheless, surplus males are still produced. Provided these calves’ welfare is protected they should become part of the meat production supply chain either as high-quality UK farm assured veal or beef."
"As we strive for improved sustainability and increase efficient use of resource in food production, we need to use every product from dairying, including calves that can be reared for meat. Our entire industry needs to work together to create a robust supply chains for high quality, farm assured British dairy beef and veal and we need to help consumers understand they should embrace these products. They are very different from intensively reared veal of the type produced in systems previously banned in the UK."
Gabbrovet Multi is the first and only ready-to-use solution licensed to treat both cryptosporidium and E.coli diarrhoea in calves.
The company highlights a study of 334 calves with severe diarrhoea, where those receiving Gabbrovet Multi showed a faster and more effective response than those given halofuginone1.
Harry Walby, ruminant veterinary advisor at Ceva Animal Health, said: “Gabbrovet Multi is the first and only ready-to-use solution for the convenient treatment of both cryptosporidium and E.coli, two of the most common causes of neonatal scour in calves."
Gabbrovet Multi can be administered in milk or water.
It is available with a dosing cap and comes in 250ml, 500ml or 1l presentations.
Gabbrovet Multi also treats gastro-intestinal infections caused by E.coli in pigs.
For further information, contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
Novartis Animal Health has launched Zolvix, billed as the first truly novel anthelmintic class for livestock to be launched in more than 25 years, together with a new drenching system designed to make drenching faster, easier and more accurate.
Zolvix contains a new active ingredient, monepantel, which kills all key sheep gastro-intestinal nematodes (roundworms), including those resistant to the existing treatments.
According to the company, the development of this new drench follows the persistent challenge from worms that have developed resistance to the three other classes of drench - white (benzimidazole or 1-BZ), yellow (levamisole or 2-LV) and clear (macrocyclic lactone or 3-ML) and combinations of these. Zolvix has a unique mode of action and so forms a fourth generation of anthelmintic, which will be known as the 4- AD, or orange drench class
Novartis Animal Health has prioritised the UK and Ireland as key launch countries for Zolvix to provide their sheep farmers with an answer to the pressing challenge of increasing anthelmintic resistance.
Lesley Stubbings, an Independent sheep consultant and Sustainable Control of Parasites in Sheep (SCOPS) panel member, said: "Resistance has become an ever increasing threat since the last new anthelmintic group was introduced to the UK market more than 25 years ago. Zolvix offers farmers a valuable opportunity to maintain good worm control and prolong the effective life of the existing products. Following the SCOPS guidelines to carefully integrate Zolvix into worm control strategies, before the other groups fail, will allow our sheep industry to reap the full benefits of this new novel group."
A study carried out by Novartis in conjunction with the Hopkirk Research Institute showed that Zolvix treated sheep gained 33.5%, or 2.8 kg deadweight, more than sheep treated with a drench to which they were resistant.
Novartis Animal Health Brand Manager Simon Harris said: "Parasite resistance is a growing problem that decreases the productivity of sheep of all ages. Many veterinarians and farmers are concerned about this, with an increasing number of farmers reporting resistance to the three groups of wormers that have been available up to now, so the introduction of Zolvix is very timely."
At the same time, the company has also launched an award-winning new drenching system designed to offer 'a superior drenching experience for both animal and operator'. The new Optiline Drencher and Optivix backpack system were developed in collaboration with drenching specialists Simcro Tech Ltd.
The Optiline Drencher has already won several design and engineering awards, including a bronze award in the 2009 NZ BEST design awards, a coveted International Forum (IF) 2010 product design award from Germany and the prestigious Bayer Innovators Award for design and engineering.
It was also a finalist in the New Zealand Agritech Innovation Awards reached the finals in three categories of the 2009 New Zealand Trade and Enterprise International Business Awards.
The Optiline drencher is coupled with a durable, light Optivix backpack that has been specially tailored to provide left or right-handed operators with the same wide range of adjustment. It also has two drench cradles - at chest and hip level - to ensure maximum comfort.
Mr Harris said: "This drencher is best appreciated during use. Contact your local Novartis Animal health representative to arrange a trial."
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
Micro-nutrition specialist Agrimin has launched All-Trace Biotin Gold, the seventh bolus in the company's All-Trace range.
The new bolus is the result of extensive in-house research and development which aimed to formulate a cost-effective, micro-nutrition bolus suitable for dry cows and heifers at risk from lameness, which affects up to 20 per cent of the UK national herd. According to Agrimin, the relationship between Biotin and its benefits on ruminant hoof health is receiving increasing attention. The company says it is the first micro-nutrition specialist to directly address this livestock health issue by using a bolus.
The Biotin Gold bolus for dairy cows and heifers delivers the target level of 20 mg per head, per day of Biotin over 120 days. In addition, the bolus also delivers the full, daily requirement of copper, cobalt, selenium and iodine as well as levels of zinc, manganese and vitamins A, D3 and E.
Administration is simple and convenient during the drying off period as many livestock are already going through a crush to have their feet trimmed and undergo other healthcare routines such as intramammary treatments.
For dry cows, two boluses are given to each cow at the point of drying off. They lie in the rumen/reticulum and slowly dissolve from a constant surface area providing a continuous and regular supply of trace elements and vitamins to the animal. The boluses dissolve completely and leave no residue in the rumen.
Agrimin says heifers respond very well to Biotin supplementation and studies have shown that supplying Biotin in the later stages of pregnancy produces the most effective results. This late stage of pregnancy is also the critical period for the transfer of vital nutrients from mother to calf and so the trace element content of All-Trace Biotin Gold will benefit both animals. Two boluses are given to each heifer at around three months pre-calving.
All-Trace Biotin Gold is available in packs of 20 boluses, which will supplement 10 cows or heifers at a cost of around £9.50 per animal for two boluses. For more information about bolus technologies and micro-nutrition, please visit www.agrimin.com or call 01652 688046.
The RCVS Disciplinary Committee has suspended a Cardigan veterinary surgeon from the RCVS Register for five months, for failure to perform accurate bovine tuberculin testing and for falsely certifying the test results.
During the two-day hearing, Dewi Wyn Lewis, of Priory Veterinary Ltd, Cardigan, answered charges about inaccurate skin fold measurements and false certification relating to two visits he made as an Official Veterinarian to a farm in April 2009 to undertake tuberculin testing.
Mr Lewis accepted that he had not carried out the tuberculin tests in the way required by Animal Health (AH) - an Executive Agency of the Department for Environment, Food and Rural Affairs - and had taken short cuts to save time. However, he denied the charges, arguing that, although instructions to Official Veterinarians clearly required the use of callipers to measure the skin folds of cattle necks on Day One of testing, not using callipers and using his finger and thumb did not amount to failing to measure.
He also argued (and it was accepted by the Committee) that, regarding Day Two of testing, there was inconsistency in AH's instructions on calliper use, which in written form required using callipers for measuring every animal but in practice accepted use of callipers when a reaction could be detected by manually palpating the skin. On Day Two, Mr Lewis said, he had done what AH required: he had used callipers on the cattle he identified for closer examination.
The Committee, however, found that by failing to use callipers on the first day, as required by AH, Mr Lewis had failed to measure the skin folds of almost all of the 104 cattle. The Committee was also satisfied that, on the second day, 10-20% of the herd were not even touched by Mr Lewis and the Committee accepted the evidence of the three other witnesses present during the testing, which indicated that Mr Lewis had failed to carry out careful assessment and manual palpation of every animal.
The Committee then considered whether Mr Lewis had dishonestly signed the certificate, or had signed a false certificate which he ought to have known was inaccurate. The Committee noted that there were no previous Disciplinary findings against Mr Lewis, and was prepared to believe his assertion that, although he knew he had not carried out the tests in strict compliance with AH's instructions, he genuinely believed his methods to be at least as accurate as measuring with callipers and did not think he was doing anything wrong or dishonest. The Committee could not then be sure that Mr Lewis had realised what he was doing was dishonest. However, the Committee noted that 'false' also means 'inaccurate' and, as Mr Lewis ought to have known that as his testing methods were not adequate, he also should have known that a considerable number of measurements on the certificate were inaccurate and that the certificate itself was inaccurate.
After considering the facts of the case, the Committee concluded that Mr Lewis's actions amounted to serious professional misconduct and directed that he should be suspended from the Register for five months, after which he may return to practice. In relation to the sanction, the Committee said: "In reaching this decision it is relevant that the false certification was not dishonest and that there was professional and personal mitigation put forward on behalf of Mr Lewis. The Committee has paid regard to the fact that Mr Lewis is an experienced veterinary surgeon who is highly thought of in his local area. It does not believe that there is any likelihood that he will repeat his previous conduct."
The Committee also said it gave considerable weight to the fact that Mr Lewis had had to wait an additional three-month period for the hearing because of an earlier adjournment.
Cryptisel is for use in reducing oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Forte says Cryptisel can be used in all new-born calves to break the cycle of transmission and multiplication on-farm.
Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said: "Cryptisel will be a very useful medicine in the control of the most commonly-identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves."
Cryptisel is a POM, available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.
For further information, contact your local Forte Territory Manager or email enquiries@fortehealthcare.com.
Procapen contains a high dose of procaine benzyl penicillin, a narrow spectrum antibiotic which targets the most important pathogens in fresh cases of mastitis in cows and is the drug of choice against benzylpenicillin-susceptible streptococci and staphlococci.
Marcus Scott, Large Animal Business Manager at Forte said: "With the widespread shortage of intramammary tubes at the moment, Procapen provides a welcome solution for many mastitis cases."
For more information, contact your local Forte Territory Manager or email: enquiries@fortehealthcare.com.
Henry, who works at Crowshall Veterinary Services in Norfolk, graduated from the Royal Veterinary College in 2018.
He is the lead products export vet for Crowshall and was instrumental in the business’s preparation for Brexit.
He is also one of the founding ‘green champions’ at the practice, which has become the first specialist poultry practice to be accredited with Investors in the Environment.
The panel of seven judges from said that within just three years Henry has gained much experience, showing evidence that he has contributed to reduced antibiotic usage as well as improved biosecurity and improved bird welfare, health and production for his clients.
They said: “He has clearly shown he has worked with colleagues as a team, and has introduced new initiatives in his practice including improving mental health of staff and assisting in sustainability.”
James Porritt, National Pig and Poultry Sales Manager of award sponsors Zoetis, said all three finalists were very strong candidates: “It was great to see the work they have all done recognised at the awards.
"It was fantastic to see Henry win and hope the award spurs him on to continue his bright future in the poultry industry.”
Photo: Henry Lamb holding the Young Farm Vet trophy, alongside Jonathan Agnew (left) and James Porritt of the award sponsors Zoetis
The draft code contains twenty recommendations to seek veterinary advice on the subject, compared to ten in the previous version, highlighting the crucial importance of veterinary surgeons' involvement in the welfare of meat chickens.
The new codes have been welcomed by the BVA, the British Veterinary Poultry Association (BVPA) and Veterinary Public Health Association (VPHA), who jointly responded to the Government consultation on the updating of the codes.
BVA President John Fishwick said: "We welcome the Government’s recognition of the vital role the veterinary profession plays in poultry welfare, with further references throughout the updated draft code to the importance of seeking veterinary advice.
"We are particularly pleased to see the recommendation that welfare outcomes should be used to assess and monitor the ongoing welfare of the birds as part of the farm health and welfare plan, and with the signposting to the Humane Slaughter Association’s Poultry Catching and Handling Technical Note within the code.
"The British poultry industry already has some of the highest welfare standards in the world and the veterinary profession and poultry industry will continue to work with Defra on further enhancing animal welfare codes to reflect best industry practice."
The draft code was placed in Parliament on 9 January 2018. If there are no objections from Parliament, it will come into force in March 2018.
Photo: Flock of Chickens (Gallus gallus domesticus) Roaming Freely in Front of Chicken Sheds on a Farm in the Rural Village of Chenson, Devon. Shutterstock / Peter Turner Photography